Angiodynamics

At the Canaccord Genuity conference, AngioDynamics presented an increased focus on a high-growth MedTech portfolio: MedTech revenue rose 18% in 2026 and now represents 47% of total revenue. For fiscal 2027, management expects MedTech growth of 12–15%, a gross margin of 54–55% and adjusted EBITDA of $13–16 million; tariffs continue to weigh on results by about $4 million. Core growth drivers are the Auryon platform, mechanical thrombectomy (AlphaVac/AngioVac) and NanoKnife, with NanoKnife recently showing strong double-digit growth and positive reimbursement decisions. The company is debt-free, generating positive cash flow and shifting production to Costa Rica to improve margins; CEO Jim Clemmer plans to retire at the end of 2026 and the board is seeking a successor. » More on de.investing.com

AngioDynamics will release results for the most recent quarter on July 14, 2026. Three analysts expect an average EPS of -0.090 USD versus -0.150 USD in the year-ago quarter; revenue is forecast at about 80.2 million USD, virtually flat year‑over‑year (+0.1%). For the just-ended fiscal year, analysts on average see a loss of -0.162 USD per share and revenue of 314.1 million USD (prior year 292.5 million USD). » More on finanzen.net

AngioDynamics has filed a patent-infringement lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of Delaware, alleging that the Hēlo thrombectomy system infringes issued patents, including a self-expanding funnel technology. The company is seeking damages and injunctive relief and says it will vigorously defend its intellectual property rights. AngioDynamics also reported strong Q3 results (EPS -0.07 USD, revenue 78.4 million USD) and reaffirmed an adjusted EBITDA outlook for 2026; analysts responded with buy ratings but lowered price targets. The stock showed movements both after the quarterly results and in premarket trading. » More on de.investing.com